Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2020
August 2020, Vol 11, No 4 | Payers' Perspectives in Oncology: ASCO 2020 Highlights
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Nivolumab plus Ipilimumab May Be a New First-Line Option for Patients with MSI-H or dMMR Metastatic Colorectal Cancer
By
Wayne Kuznar
Colon Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
The first-line immunotherapy combination of nivolumab (Opdivo) and low-dose ipilimumab (Yervoy) continues to show robust, durable clinical benefit, with a deepening of response, in patients with microsatellite instability high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer (CRC), according to results presented at the ASCO 2020 virtual annual meeting.
Read More
Pembrolizumab Doubles Progression-Free Survival in Subset of Patients with Metastatic Colorectal Cancer
By
Chase Doyle
Colon Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
There is a new standard of care in the first-line treatment setting for the subset of patients with advanced colorectal cancer (CRC) that is associated with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR), according to data presented at the ASCO 2020 virtual annual meeting.
Read More
CAR T-Cell Therapy Shows Deep, Durable Responses in Relapsed or Refractory Multiple Myeloma
By
Chase Doyle
Multiple Myeloma
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Cellular therapy is becoming an attractive option for heavily pretreated patients with relapsed or refractory multiple myeloma.
Read More
Pembrolizumab Added to First-Line Chemotherapy Improves Progression-Free Survival in Metastatic TNBC
By
Wayne Kuznar
Breast Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Pembrolizumab (Keytruda) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy alone as a first-line treatment for patients with metasstatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.
Read More
No Survival Benefit with Surgery and Radiation Added to Systemic Therapy in Patients with Newly Diagnosed Stage IV Breast Cancer
By
Phoebe Starr
Breast Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Early locoregional therapy with surgery and radiation does not improve overall survival (OS) in women with newly diagnosed stage IV breast cancer and an intact primary tumor compared with systemic therapy alone, according to the results of the randomized ECOG-ACRIN E2108 phase 3 clinical trial.
Read More
ASCO 2020 Presidential Address: Accelerating Progress, Prioritizing Diversity
By
Wayne Kuznar
Value-Based Care
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
When ASCO President Howard A. Burris III, MD, FACP, FASCO, chose the theme for the 2020 annual meeting—“Unite and Conquer: Accelerating Progress Together”—early last year, he never imagined that it would take on new meaning just 12 months later.
Read More
FDA News: August 2020
FDA Approvals, News & Updates
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
Inqovi First Oral Hypomethylating Agent Approved for Intermediate- or High-Risk Myelodysplastic Syndromes
Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer
Opdivo Now Approved for Advanced Esophageal Squamous-Cell Carcinoma
Cyramza plus Tarceva Approved for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
Tecentriq plus Avastin Combination Approved for First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma
Opdivo plus Yervoy and Limited Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression
Read More
Olaparib Extends Survival by >1 Year in Patients with Ovarian Cancer and BRCA Mutation, Ushering in Personalized Medicine in This Malignancy
By
Wayne Kuznar
Ovarian Cancer
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
With follow-up of more than 5 years, women with relapsed platinum-sensitive ovarian cancer and a
BRCA
mutation who participated in the multicenter phase 3 SOLO2 clinical trial lived more than 1 year longer when randomized to maintenance therapy with the poly (ADP- ribose) polymerase (PARP) inhibitor olaparib (Lynparza) compared with placebo, according to data released at the ASCO 2020 virtual annual meeting.
Read More
The WEE1 Inhibitor Adavosertib Displays Promising Clinical Activity in Uterine Serous Cancer
By
Wayne Kuznar
Emerging Therapies
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
The small-molecule inhibitor of tyrosine kinase WEE1 adavosertib demonstrated promising clinical activity in a single-arm, phase 2 study of patients with unselected uterine serous cancer (USC), with an objective response rate of 29.4%, said Joyce F. Liu, MD, MPH, Director of Clinical Research, Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, at the ASCO 2020 virtual annual meeting.
Read More
Intratumoral Injection of Cisplatin and Vinblastine, with or without Pembrolizumab, Improves Intracellular Transport in Patients with Advanced Solid Tumors
By
Chase Doyle
Emerging Therapies
August 2020, Vol 11, Special Issue: Payers' Perspectives in Oncology
A novel intratumoral chemotherapy agent delivered by direct injection permits the dispersion of cytotoxic drugs into cancer cells to eradicate tumors. Data from a phase 1/2 trial of intratumoral INT230-6, alone and in combination with pembrolizumab (Keytruda), in patients with advanced solid tumors was presented at the ASCO 2020 virtual annual meeting.
Read More
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma